Atlas Trials

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT02222948 · TERMINATED

Trial details

NCT number
NCT02222948
Sponsor
Genzyme, a Sanofi Company
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsing-remitting Multiple Sclerosis
Start date
2014-09-01
Primary completion
2016-04-01
Enrollment
112

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.